ContraFect

$4.25
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.12 (-2.78%) Today
+$0.06 (+1.43%) As of 12:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ContraFect and other stocks, options, and ETFs commission-free!

About CFRX

ContraFect Corporation Common Stock, also called ContraFect, is a clinical stage biotechnology company, which engages in discovering and developing direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins and Amurin Peptides.

CEO
Roger J. Pomerantz
Employees
33
Headquarters
Yonkers, New York
Founded
2008
Market Cap
174.74M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.41M
High Today
$4.39
Low Today
$4.16
Open Price
$4.25
Volume
1.32M
52 Week High
$8.45
52 Week Low
$4.11

CFRX Earnings

-$1.11
-$0.74
-$0.37
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 14, Pre-Market

You May Also Like

EUCR
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure